Loomis Sayles & CO L P Aerie Pharmaceuticals Inc Call Options Transaction History

Loomis Sayles & CO L P

  • $76.2 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding AERI

# of Institutions
3
Shares Held
2.4M
Call Options Held
0
Put Options Held
0
View Full List

About AERIE PHARMACEUTICALS INC

AERI Quotes by TradingView
  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email